Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Actinium Pharmaceuticals schedules a September 14, 2026 investor presentation and offers one-on-one meetings at the H.C. Wainwright conference.
Rhea-AI Summary
Actinium Pharmaceuticals (ATNM) will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, in New York, NY. Chairman and CEO Sandesh Seth is scheduled to present from 3:00 to 3:30 p.m. ET, and company management will be available for one-on-one investor meetings.
Positive
- None.
Negative
- None.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Aug 14 | IP and listing update | Positive | +1.0% | Patent advances and NYSE compliance plan accompanied manufacturing updates |
| Jun 3 | Preclinical lung data | Positive | -4.9% | ATNM-400 data supported activity in KRAS- and EGFR-mutant models |
| Jun 3 | Preclinical prostate data | Positive | -4.9% | ATNM-400 showed activity in resistant prostate cancer models |
| Jun 1 | Leadership appointment | Positive | -6.3% | Oncology expert appointed chief medical officer for pipeline development |
| Jun 1 | Radiochemistry data | Positive | -6.3% | Chelator optimization improved targeting and pharmacokinetic characteristics |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Historical responses were mostly negative for positive or development-focused announcements, with four negative reactions and one positive reaction of 0.96%.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Details
Event: H.C. Wainwright 28th Annual Global Investment Conference
Presentation Date and Time: Monday, September 14, 2026, 3:00 – 3:30 p.m. ET
Location:
Registered conference attendees may request a one-on-one meeting with management through their H.C. Wainwright representative.
About Actinium Pharmaceuticals, Inc.
Actinium is a pioneer in targeted radiotherapies designed to improve outcomes for patients with cancer. The company employs a biology-driven approach to develop differentiated radiopharmaceuticals for solid tumors and hematologic malignancies. Its mission is to transform cancer treatment through innovative radioconjugates that maximize therapeutic efficacy while minimizing toxicity to healthy tissue by combining expertise in tumor biology, translational medicine, and radiochemistry. Since inception, Actinium has focused on developing innovative radiotherapies. Its pipeline reflects this strategy across three areas: (1) solid tumor therapeutics including ATNM-400 and Actimab-A with pan-tumor potential; (2) Actimab-A as a therapeutic backbone for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in collaboration with the National Cancer Institute (NCI); and (3) targeted conditioning agents including Iomab-B for bone marrow transplant and Iomab-ACT for cell and gene therapy conditioning. ATNM-400 targets a novel antigen distinct from PSMA and has demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Actimab-A has shown improved survival in relapsed/refractory AML with CLAG-M and is advancing toward a Phase 2/3 trial, with additional development ongoing through a CRADA with the NCI. Actinium is also advancing preclinical solid tumor programs and holds ~250 patents and patent applications, including intellectual property related to cyclotron-based production of Ac-225. For more information, please visit www.actiniumpharma.com.
Forward-Looking Statements
This press release may contain projections or other "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995 regarding future events or the future financial performance of the Company which the Company undertakes no obligation to update. These statements are based on management's current expectations and are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with the timing and outcome of the Company's clinical milestones and data readouts, preliminary study results varying from final results, the scope, validity and enforceability of the Company's intellectual property, the Company's ability to maintain the listing of its common stock on the NYSE American, estimates of potential markets for drugs under development, clinical trials, actions by the FDA and other governmental agencies, regulatory clearances, responses to regulatory matters, the market demand for and acceptance of Actinium's products and services, performance of clinical research organizations and other risks detailed from time to time in Actinium's filings with the Securities and Exchange Commission (the "SEC"), including without limitation its most recent annual report on Form 10-K, subsequent quarterly reports on Forms 10-Q and Forms 8-K, each as amended and supplemented from time to time.
Investors: investorrelations@actiniumpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/actinium-pharmaceuticals-inc-to-present-at-the-hc-wainwright-28th-annual-global-investment-conference-302870066.html
SOURCE Actinium Pharmaceuticals, Inc.
FAQ
When will Actinium Pharmaceuticals (ATNM) present at the H.C. Wainwright 28th Annual Global Investment Conference?
Actinium Pharmaceuticals is scheduled to present on Monday, September 14, 2026, from 3:00 to 3:30 p.m. ET at the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY.
Who will present for Actinium Pharmaceuticals (ATNM) at the H.C. Wainwright 2026 conference?
Sandesh Seth, Chairman and Chief Executive Officer of Actinium Pharmaceuticals, will deliver the company’s presentation at the H.C. Wainwright 28th Annual Global Investment Conference.
Where is the H.C. Wainwright 28th Annual Global Investment Conference featuring Actinium Pharmaceuticals (ATNM) being held?
The H.C. Wainwright 28th Annual Global Investment Conference, at which Actinium Pharmaceuticals will present, is being held in New York, NY from September 14–16, 2026.
How can investors request one-on-one meetings with Actinium Pharmaceuticals (ATNM) at the H.C. Wainwright conference?
Registered conference attendees may request a one-on-one meeting with Actinium Pharmaceuticals’ management through their H.C. Wainwright representative, as stated for the 28th Annual Global Investment Conference.